Skip to main content

Table 1 Clinical characteristics of the study cohorts

From: Genetic variants in the circadian rhythm pathway as indicators of prostate cancer progression

Characteristic  
Localized prostate cancer cohort
 Patients, n 458
 Age at diagnosis
  Median, years (IQR) 66 (61–70)
 PSA at diagnosis
  Median, ng/mL (IQR) 11.1 (7.1–17.5)
 Pathologic Gleason score, n (%)
  < 7 160 (35.3)
  7 232 (51.2)
  > 7 61 (13.5)
 Pathologic stage, n (%)
  T1/T2 303 (67.2)
  T3/T4/N1 148 (32.8)
  M1 0 (0.0)
 Disease progression
  No 274 (59.8)
  Yes 184 (40.2)
Advanced prostate cancer cohort
 Patients, n 324
 Age at diagnosis
  Median, years (IQR) 72 (66–78)
 PSA at ADT initiation
  Median, ng/mL (IQR) 32.6 (9.4–123.4)
 Biopsy Gleason score at diagnosis, n (%)
  < 7 70 (22.2)
  7 131 (41.5)
  > 7 115 (36.4)
 Clinical stage at diagnosis, n (%)
  T1/T2 92 (28.6)
  T3/T4/N1 103 (32.0)
  M1 127 (39.4)
 PSA nadir
  Median, ng/mL (IQR) 0.12 (0.01–1.08)
 Treatment modality
  ADT as primary treatment 138 (42.7)
  ADT for post RP PSA failure 39 (12.1)
  ADT for post RT PSA failure 6 (1.9)
  Neoadjuvant/adjuvant ADT with RT 101 (31.3)
  Others 39 (12.1)
 Disease progression
  No 28 (8.6)
  Yes 296 (91.4)
  1. IQR, interquartile range; PSA, prostate-specific antigen; ADT, androgen-deprivation therapy; RP, radical prostatectomy; RT, radiation therapy